ESSA Pharma: Funding, Investors & Team (Sep 2026)
ESSA is a drug organization zeroed in on the improvement of little particle drugs for the therapy of malignant growth, with an emphasis on cutting edge prostate disease. ESSA is creating drugs that specifically block the N-terminal space of the androgen receptor (AR). The AR is expected for the development and endurance of most prostate malignant growth; hence, the AR N-terminal space is an optimal objective for cutting edge chemical treatment.
ESSA Pharma has raised $13.6M across 1 funding round on record, the most recent a Post-IPO Equity of $13.6M announced in Jul 2022.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
ESSA Pharma Company Profile and Key Stats
Latest funding round on record: Jul 2022.
ESSA Pharma Funding Rounds
ESSA Pharma Founders and Leadership Team
No contact details are on record for this team yet.
ESSA Pharma Funding Compared to Other Biotechnology Startups
ESSA Pharma's latest round of $13.6M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like ESSA Pharma in Biotechnology and Vancouver
Companies Similar to ESSA Pharma
Medicenna is a clinical-stage immunotherapy company focused on oncology and the development and…
Cybin is a clinical-stage biopharmaceutical company on a mission to create safe and effective…
Hemostemix Inc. is a Canadian biotechnology company that specializes in creating blood-derived cell therapies…
Avicanna is an organization in the biopharmaceutical sector that concentrates on enhancing medical cannabis…
Edesa Biotech is a privately-held company in the clinical stage that specializes in creating therapies for…
ME Therapeutics is a biotech company that specializes in finding and creating drugs for immuno-oncology that…
Aurinia Pharmaceuticals is a clinical stage biopharmaceutical company focused on developing and…
Medicus Pharma is a biotechnology research company that fast-tracks the progress of life sciences and…
ProteinQure is a biotechnology company specializing in creating innovative peptides for various medical…
Anodyne's mission is to create critical chemicals sustainably. Anodyne's approach takes advantage of nature's…
NervGen Pharma is a medicine company dedicated to creating solutions for the treatment of nerve damage and…
ZYUS is a biopharmaceutical company focused on providing patients with cannabinoids and other plant-based…
ESSA Pharma Funding FAQs
What does ESSA Pharma do?
ESSA is a drug organization zeroed in on the improvement of little particle drugs for the therapy of malignant growth, with an emphasis on cutting edge prostate disease. ESSA is creating drugs that specifically block the N-terminal space of the androgen receptor (AR). The AR is expected for the development and endurance of most prostate malignant growth; hence, the AR N-terminal space is an optimal objective for cutting edge chemical treatment.
How much funding has ESSA Pharma raised?
ESSA Pharma has raised $13.6M across 1 round on record. The most recent is a Post-IPO Equity of $13.6M announced in Jul 2022.
When did ESSA Pharma last raise funding?
ESSA Pharma's most recent funding round on record is a Post-IPO Equity of $13.6M, announced in Jul 2022.
Who founded ESSA Pharma?
FundedIQ lists Raymond Andersen (Founder) at ESSA Pharma.
Where is ESSA Pharma headquartered?
ESSA Pharma is based in Vancouver, British Columbia, Canada.
How many employees does ESSA Pharma have?
ESSA Pharma is in the 11-50 employee band.
How does ESSA Pharma's funding compare to other Biotechnology startups?
ESSA Pharma's latest round of $13.6M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,182 tracked companies over the last two years.
About FundedIQ's ESSA Pharma Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for ESSA Pharma is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.